Skip to main content
. 2014 May 7;9(5):e96575. doi: 10.1371/journal.pone.0096575

Figure 3. Gene and Protein Expression for Ppp1r1b/DARPP-32.

Figure 3

(A) Gene expression for Ppp1r1b/DARPP-32 in control striatal STHdh cells (CTL, open bars) and HPRT-knockdown (HPRTKD, closed bars). Bars represent mean ±SEM (n = 4). mRNA expression is normalized to GAPDH mRNA level (*P<0.05, t-test). (B) Immuno-blot and quantification of DARPP-32 protein expression in striatal cells. The quantification bar graphs are shown as means ± SEM (n = 3, *P<0.05, t-test). (C) Gene expression for Ppp1r1b/DARPP-32 in the striatum of wild-type (WT, open bars) and HPRT knockout (HPRTKO, closed bars) mice. Bars represent mean ±SEM (n = 4). mRNA expression is normalized to GAPDH RNA level (*P<0.05, t-test). (D) Immuno-blot and quantification of DARPP-32 protein expression in the striatum of WT and HPRTKO mice. The quantification bar graphs are shown as means ± SEM (n = 3, *P<0.05, t-test). (E) DARPP-32 phosphoprotein (Thr34) expression in response to D1R (SKF393298) agonist treatment (50 µM). Immuno-blot and quantification of Thr34-DARPP-32 in control and HPRT-deficient striatal cells, the quantification bar graphs are shown as means ± SEM (n = 6, *P<0.05). (F) Thr34-DARPP-32 phosphoprotein expression in striatal tissue of WT (open bar) and HPRTKO (closed bar) mice (n = 3, *P<0.05).